ImmunoPrecise Antibodies Ltd.
IPA
$0.45
-$0.0139-3.00%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.75% | 5.47% | 9.88% | 16.97% | 13.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.75% | 5.47% | 9.88% | 16.97% | 13.14% |
| Cost of Revenue | 1.49% | 12.22% | 25.89% | 34.85% | 26.42% |
| Gross Profit | -2.84% | -0.45% | -3.33% | 2.86% | 3.10% |
| SG&A Expenses | 4.67% | 4.85% | 0.58% | 0.80% | -12.03% |
| Depreciation & Amortization | -30.47% | -33.27% | -35.01% | -33.71% | -3.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.46% | 3.50% | -7.16% | -18.12% | -23.17% |
| Operating Income | -8.39% | -0.33% | 26.46% | 46.68% | 51.72% |
| Income Before Tax | -215.25% | -76.68% | -34.30% | -1.08% | 41.77% |
| Income Tax Expenses | -128.68% | -123.31% | -106.68% | -77.70% | -1,297.62% |
| Earnings from Continuing Operations | -228.85% | -72.93% | -30.08% | 2.34% | 49.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -228.85% | -72.93% | -30.08% | 2.34% | 49.39% |
| EBIT | -8.39% | -0.33% | 26.46% | 46.68% | 51.72% |
| EBITDA | -38.29% | -21.04% | 27.47% | 56.22% | 64.51% |
| EPS Basic | -182.70% | -61.62% | -22.59% | 7.29% | 51.85% |
| Normalized Basic EPS | -4.66% | -1.74% | 26.36% | 47.21% | 53.87% |
| EPS Diluted | -182.70% | -61.62% | -22.59% | 7.29% | 51.85% |
| Normalized Diluted EPS | -4.66% | -1.74% | 26.36% | 47.21% | 53.87% |
| Average Basic Shares Outstanding | 13.70% | 7.63% | 4.73% | 2.97% | 5.89% |
| Average Diluted Shares Outstanding | 13.70% | 7.63% | 4.73% | 2.97% | 5.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |